BRTX (biorestorative.com) יחס שווי שוק לשווי בספרים
BioRestorative Therapies brings together an elite group of cell biologists, attracted by creative freedom and stock options. The business's financial stability relies on external investments and test results, as operating income stands at 0.57. The GURU.Markets quotes provided below illustrate the company's share price action. Currently, the R&D center is accelerating the release of the BRTX-100 drug, creating an intensive innovation pipeline to combat back pain.
BRTX (BioRestorative Therapies): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The localization of BioRestorative Therapies (BRTX) research in the US minimizes external risks and protects intellectual property. This chart of market capitalization to book value allows for an assessment of the business's real net asset value. The metric compares the company's market value with its book capital to identify overvaluation. Extreme peaks signal a risk of correction, while deep troughs indicate potential stagnation. This indicator objectifies the fundamental value of capital.